Ovid Therapeutics Inc. Share Price & Technical Analysis
OVID · $2.47 (+1.23%)
Healthcare / Biotechnology
$2.47
+1.23%
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human ora…
Price chart
Seasonality
May has 1 positive and 2 negative years (last 5 years shown)
-11% return in May, 1% avg return in past 3 year May month.
54% return in 2026, 66% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 38% | 27% | -11% | – | – | – | – | – | – | – | 54% |
| 25 | -22% | -29% | -50% | 0% | 0% | 0% | 67% | 160% | 8% | 8% | 29% | -6% | 165% |
| 24 | 22% | -13% | -14% | -3% | 3% | -74% | 43% | 10% | 9% | -8% | 0% | -18% | -44% |
| 23 | 32% | 0% | 4% | 44% | 0% | -6% | 9% | -6% | 12% | -8% | -14% | 10% | 77% |
| 22 | -12% | 21% | -9% | -12% | -35% | 29% | -5% | 0% | -10% | -16% | 13% | 6% | -30% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$481.91M
P/E ratio
—
52W high
$3.10
52W low
$0.27
Volume
13,39,322
Beta
0.18
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ovid Therapeutics Inc. share price today?
- Ovid Therapeutics Inc. (OVID) last traded around $2.47 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does OVID have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for OVID. Download the app for real-time alerts.
- How can I analyze Ovid Therapeutics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.